ARM / Defence Therap - LARVOL DELTA

A1-reprogrammed mesenchymal stromal cells prime potent antitumoral responses. (PubMed, iScience) - "By evaluating ARM-based cellular vaccine in mouse models of lymphoma and melanoma, we observe significant therapeutic potency, particularly in allogeneic setting and in combination with anti-PD-1 immune checkpoint inhibitor. Overall, this study introduces a strong target for developing an antigen-adaptable vaccination platform, capable of synergizing with immune checkpoint blockers to trigger tumor regression, supporting further investigation of ARMs as an effective and versatile anti-cancer vaccine."

Journal • Stroma • Hematological Malignancies • Lymphoma • Melanoma • Oncology • Solid Tumor • CD8

DEFENCE’S MELANOMA TARGETED VACCINE A1-REPROGRAMMED MSC (ARM) CELL POTENCY VALIDATED (PharmiWeb) - "Defence Therapeutics Inc...is pleased to report the validation of its ARM vaccine candidate in a melanoma model with a cure rate of 60%....Defence is currently working to begin the manufacturing of its ARM vaccine in Q1 of 2023 with the objective to start treating patients in Phase I clinical cancer trial with solid tumors by Q3/Q4 of 2023."

New P1 trial • Pipeline update • Melanoma • Oncology • Skin Cancer